Molecular biomarker set for early detection of ovarian cancer

• US 9,914,974 B2
• Filed: 06/09/2015
• Issued: 03/13/2018
• Est. Priority Date: 03/08/2011
• Status: Active Grant

• Current Assignee: King Abdullah University of Science and Technology
• Original Assignee: King Abdullah University of Science and Technology
• Inventors: Bajic, Vladimir, Kaur, Mandeep
• Primary Examiner(s): Wu, Julie
• Application Number:
  US14/734,190
• Publication Number:
  US 20150284809A1
• Time in Patent Office: 1,008 Days
• Field of Search: None
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/47 Assays involving proteins of known structure or function as defined in the subgroups
• CPC Class Codes: G01N 2800/50 Determining the risk of developing a disease
• CPC Class Codes: G01N 33/57449 of ovaries
• CPC Class Codes: Y10T 436/143333 Saccharide [e.g., DNA, etc.]

Abstract

Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Claims

1. A method of identifying an individual to be treated for ovarian cancer, consisting of:

a) detecting expression levels of TFAP2A, E2F5, and CA125from a sample obtained from the individual;

b) selecting the individual for treatment when expression levels of TFAP2A, E2F5, and CA125 are higher relative to the expression levels of TFAP2A, E2F5, and CA125 from a control; and

c) administering to the individual a treatment for ovarian cancer, wherein the treatment for ovarian cancer is selected from the group consisting of surgery, radiation, and chemotherapy.

2. The method of claim 1, wherein the expression levels are determined by protein level or mRNA level of TFAP2A, CA125 and E2F5.

3. The method of claim 2, wherein the protein level of TFAP2A, CA125 and E2F5 is determined with an antibody.

4. The method of claim 2, wherein the mRNA levels of TFAP2A, CA125 and E2F5 from the individual are determined.

5. The method of claim 2, wherein the mRNA level is determined from ovarian tissue or blood from the individual.

6. The method of claim 1, wherein the control is tissue or blood from one or more normal individuals or is from tissue or blood from the individual.

7. The method of claim 1, wherein the method detects the stage of ovarian cancer in the individual.

8. The method of claim 7, wherein the stage is stage IA, IC, IIIC, or a combination thereof.

10. The method of claim 1, wherein the sample is ovarian tissue, blood, serum, or plasma.

11. The method of claim 1, wherein the chemotherapy includes administering a chemotherapeutic agent selected from the group consisting of drugs that contain platinum and taxane compounds.

12. The method of claim 11, wherein the chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin, and paclitaxel.

13. The method of claim 1, wherein chemotherapy comprises administering an effective amount of melphalan, doxorubicin, altretamine, 5-fluorouracil, topotecan, ifosamide, and etoposide.

9. A method of identifying an individual to be treated for ovarian cancer, consisting of:

a) detecting expression levels of TFAP2A, E2F5, and CA125 from a sample obtained from the individual;

b) selecting the individual for treatment when expression levels of TFAP2A, E2F5, and CA125 are higher relative to the expression levels of TFAP2A, E2F5, and CA125 from a control;

c) performing an additional ovarian cancer detection method; and

d) administering to the individual a treatment for ovarian cancer, wherein the treatment for ovarian cancer is selected from the group consisting of surgery, radiation, and chemotherapy, and wherein the additional ovarian cancer detection method is selected from the group consisting of palpitation, ultrasound, magnetic resonance imaging, X-ray, CT scan, blood testing, and biopsy.